AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7667550 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio Frequency (RF) at a SAR of 2.5 W/kg
Number of subjects: 4
Study 7667550 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm Water (WW) at 40 degrees C
Number of subjects: 4
Study 7667550 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulated Sack (IS)
Number of subjects: 4
Study 2669567 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with standardized Bermuda grass pollen extract
Number of subjects: 30
Study 2669567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1013666 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (Blocadren) 15-20 mg daily
Number of subjects: 24
Study 1013666 — intervention group
Group type: COMPARATOR
Intervention: Moduretic (baseline diuretic therapy)
Number of subjects: 24
Study 30904880 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised insole plus usual care
Number of subjects: 76
Study 30904880 — intervention group
Group type: COMPARATOR
Intervention: Standard insole plus usual care
Number of subjects: 76
Study 28246136 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessing IPV
Number of subjects: 3427
Study 28246136 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessing IPV and experiencing violence
Number of subjects: 3427
Study 25713382 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory enrichment with audio recordings of maternal sounds (mother's voice and heartbeat)
Number of subjects: 40
Study 25713382 — intervention group
Group type: COMPARATOR
Intervention: Routine exposure to hospital environmental noise
Number of subjects: 40
Study 23260547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose autologous muscle derived cells (1, 2, 4, 8 or 16 × 10(6))
Number of subjects: 38
Study 23260547 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose autologous muscle derived cells (32, 64 or 128 × 10(6))
Number of subjects: 38
Study 22042887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) therapy
Number of subjects: 73
Study 22042887 — intervention group
Group type: COMPARATOR
Intervention: High-Pressure Balloon (HPB) therapy
Number of subjects: 73
Study 18436157 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (250 mg intravenously twice a day for 14 days)
Number of subjects: 32
Study 18436157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17145529 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin plus 5-fluorouracil (PF) (n = 41)
Number of subjects: 75
Study 17145529 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin plus gemcitabine (PG) (n = 34)
Number of subjects: 75
Study 17145529 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin replaced by carboplatin in concurrent cycles (n = 18)
Number of subjects: 75
Study 12365864 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-coated MAC (CC-MAC) stent
Number of subjects: 46
Study 12365864 — intervention group
Group type: COMPARATOR
Intervention: Uncoated MAC (UC-MAC) stent
Number of subjects: 46
Study 10492544 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol reduction device during air polishing
Number of subjects: 30
Study 10492544 — intervention group
Group type: COMPARATOR
Intervention: Air polisher without aerosol reduction device
Number of subjects: 30
Study 7571663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime plus metronidazole (single dose)
Number of subjects: 1010
Study 7571663 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (control)
Number of subjects: 1010
Study 7235354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, sublingual)
Number of subjects: 10
Study 7235354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mg, sublingual)
Number of subjects: 10
Study 31364435 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (n=20)
Number of subjects: 36
Study 31364435 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (n=16)
Number of subjects: 36
Study 31364435 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=16)
Number of subjects: 36
Study 30124230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal vitamin A supplementation
Number of subjects: 198
Study 30124230 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-child stimulation
Number of subjects: 198
Study 30124230 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and physical punishment
Number of subjects: 198
Study 30124230 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education (completion of primary school)
Number of subjects: 198
Study 30124230 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height (<155 cm)
Number of subjects: 198
Study 30124230 — intervention group
Group type: COMPARATOR
Intervention: Prenatal zinc supplementation
Number of subjects: 198
Study 28219060 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 204
Study 28219060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Prednisolone
Number of subjects: 204
Study 28219060 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only (WAT)
Number of subjects: 204
Study 26692981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlink-embedded journal article
Number of subjects: 44
Study 26692981 — intervention group
Group type: COMPARATOR
Intervention: Unmodified journal article
Number of subjects: 44
Study 24265681 — intervention group
Group type: EXPERIMENTAL
Intervention: In Favor of Myself program
Number of subjects: 259
Study 24265681 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 259
Study 21613332 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment group treatment (6 sessions of 2 hours each)
Number of subjects: 151
Study 21613332 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 151
Study 21613332 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment group treatment
Number of subjects: 151
Study 18047521 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 271
Study 18047521 — intervention group
Group type: COMPARATOR
Intervention: methotrexate (MTX)
Number of subjects: 271
Study 18047521 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 271
Study 16644338 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil sustained release (SR) strategy
Number of subjects: 8045
Study 16644338 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR strategy
Number of subjects: 8045
Study 16644338 — intervention group
Group type: COMPARATOR
Intervention: Atenolol strategy
Number of subjects: 8045
Study 16644338 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril in the verapamil SR strategy
Number of subjects: 8045
Study 16644338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 8045
Study 14618464 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (group 1A)
Number of subjects: 48
Study 14618464 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet after 4 years (group 1B)
Number of subjects: 48
Study 14618464 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (group 2A)
Number of subjects: 48
Study 14618464 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched controls (group 2B)
Number of subjects: 48
Study 11030397 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection of the lingual nerve during lower third molar removal
Number of subjects: 300
Study 11030397 — intervention group
Group type: COMPARATOR
Intervention: No protection of the lingual nerve during lower third molar removal
Number of subjects: 300
Study 9058850 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic Study guided therapy
Number of subjects: 0
Study 9058850 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiographic Monitoring guided therapy
Number of subjects: 0
Study 9058850 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol therapy
Number of subjects: 0
Study 9058850 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of previous antiarrhythmic drug therapy
Number of subjects: 0
Study 8198263 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg intravenously
Number of subjects: 541
Study 8198263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 3069004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit-flavoured mask
Number of subjects: 41
Study 3069004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water-moistened mask)
Number of subjects: 41
Study 29700127 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐alfatide II
Number of subjects: 44
Study 29700127 — intervention group
Group type: COMPARATOR
Intervention: 18F‐FDG
Number of subjects: 44
Study 29700127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 18F‐alfatide II and 18F‐FDG
Number of subjects: 44
Study 26675055 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal danazol (200mg BID, 30 days before surgery)
Number of subjects: 160
Study 26675055 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diphereline (twice with a 28‐day interval)
Number of subjects: 160
Study 26675055 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal danazol
Number of subjects: 160
Study 26675055 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diphereline
Number of subjects: 160
Study 25335962 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxa cone moxibustion and routine care
Number of subjects: 120
Study 25335962 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxa box moxibustion and routine care
Number of subjects: 120
Study 25335962 — intervention group
Group type: COMPARATOR
Intervention: Routine care for stroke recovery
Number of subjects: 120
Study 25335962 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 22972524 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25-100 µg
Number of subjects: 351
Study 22972524 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 100-400 µg (tablet)
Number of subjects: 351
Study 22972524 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25-50 µg
Number of subjects: 351
Study 20804428 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled dry powder inhalers
Number of subjects: 0
Study 20804428 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation instruction
Number of subjects: 0
Study 20804428 — intervention group
Group type: COMPARATOR
Intervention: Multiple inhaler devices
Number of subjects: 0
Study 20804428 — intervention group
Group type: COMPARATOR
Intervention: No inhalation instruction
Number of subjects: 0
Study 17687648 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus gefitinib 250 mg daily from day 5 to 16 (Arm A)
Number of subjects: 90
Study 17687648 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus gefitinib 250 mg daily from day 1 to 21 (Arm B)
Number of subjects: 90
Study 17687648 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus placebo (Arm C)
Number of subjects: 90
Study 17687648 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Arms A + B (gefitinib)
Number of subjects: 90
Study 17687648 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (intermittent gefitinib)
Number of subjects: 90
Study 17687648 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (continuous gefitinib)
Number of subjects: 90
Study 17687648 — intervention group
Group type: COMPARATOR
Intervention: Arm C (placebo)
Number of subjects: 90
Study 16861734 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (20 mg/kg, intravenously three times a week after each haemodialysis session)
Number of subjects: 21
Study 11882101 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive public health nursing case management
Number of subjects: 129
Study 11882101 — intervention group
Group type: COMPARATOR
Intervention: Self-directed approach (Control)
Number of subjects: 129
Study 9806512 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with 4 ml of 10% lidocaine solution during intracavitary brachytherapy
Number of subjects: 40
Study 9806512 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered during intracavitary brachytherapy
Number of subjects: 40
Study 9806512 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with 10% lidocaine solution
Number of subjects: 40
Study 7564921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.0 g/day)
Number of subjects: 18
Study 7564921 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil (4.0 g/day)
Number of subjects: 18
Study 2539206 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.3 mg/kg)
Number of subjects: 43
Study 2539206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 414205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged intravenous infusion of trinitrin for 24 hours in 12 cases and during 5 at 7 days in 27 cases
Number of subjects: 74
Study 414205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged intravenous infusion of trinitrin
Number of subjects: 74
Study 414205 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 7033781 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)
Number of subjects: 136
Study 7033781 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 136
Study 7033781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 31010033 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU of VitD3
Number of subjects: 22
Study 31010033 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of BPH
Number of subjects: 22
Study 31010033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VitD3 and BPH
Number of subjects: 22
Study 31010033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29313400 — intervention group
Group type: EXPERIMENTAL
Intervention: GoFAR intervention
Number of subjects: 30
Study 29313400 — intervention group
Group type: EXPERIMENTAL
Intervention: FACELAND intervention
Number of subjects: 30
Study 29313400 — intervention group
Group type: COMPARATOR
Intervention: CONTROL group
Number of subjects: 30
Study 27043168 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 100-300 mg after each HD session for one month
Number of subjects: 54
Study 27043168 — intervention group
Group type: COMPARATOR
Intervention: Placebo thrice weekly after each HD session
Number of subjects: 54
Study 24474818 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan plus cisplatin
Number of subjects: 220
Study 24474818 — intervention group
Group type: COMPARATOR
Intervention: etoposide plus cisplatin
Number of subjects: 220
Study 22662738 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based version of the Community Reinforcement Approach plus motivational incentives
Number of subjects: 500
Study 22662738 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 500
Study 19733905 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen patches (n = 21)
Number of subjects: 37
Study 19733905 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches (n = 16)
Number of subjects: 37
Study 18161401 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM/EE
Number of subjects: 2894
Study 18161401 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone acetate/EE
Number of subjects: 2894
Study 15326195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 2948
Study 15326195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus a new agent
Number of subjects: 2948
Study 15326195 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus a new agent
Number of subjects: 2948
Study 15326195 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy
Number of subjects: 2948
Study 11913295 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide whitening strips
Number of subjects: 0
Study 9510218 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (0.1 mg/kg intravenously)
Number of subjects: 14
Study 9510218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7696003 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational seminar series for hospice staff about AIDS care
Number of subjects: 63
Study 7696003 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified intervention)
Number of subjects: 63
Study 2909150 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (3 mg/kg over 3 minutes)
Number of subjects: 8
Study 2909150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml of saline over 3 minutes)
Number of subjects: 8
Study 71974 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg
Number of subjects: 0
Study 71974 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 100 mg
Number of subjects: 0
Study 71974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31436378 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid 5% mouth wash 3 times daily
Number of subjects: 40
Study 31436378 — intervention group
Group type: COMPARATOR
Intervention: Kenalog in Orabase twice daily
Number of subjects: 40
Study 30942009 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupunture applied at specific acupuncture points (Liangqiu, Xuehai, Yinlingquan, Zusanli, Fenglong, Qiuxu) for 30 minutes once a day from the 1st to 7th day after surgery
Number of subjects: 40
Study 30942009 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupunture
Number of subjects: 40
Study 30942009 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional patient controlled epidural analgesia and oral celecoxib)
Number of subjects: 40
Study 30942009 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 30650498 — intervention group
Group type: EXPERIMENTAL
Intervention: RPH with the simplified M-M surgery
Number of subjects: 1200
Study 30650498 — intervention group
Group type: COMPARATOR
Intervention: PPH with the simplified M-M surgery
Number of subjects: 1200
Study 25740292 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg day -1)
Number of subjects: 30
Study 25740292 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study 26280611 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximally coated femoral components (Group A)
Number of subjects: 207
Study 26280611 — intervention group
Group type: COMPARATOR
Intervention: Fully coated femoral components (Group B)
Number of subjects: 207
Study 23113678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 6
Study 23113678 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 6
Study 19707065 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental curriculum delivery (modules received over several weeks)
Number of subjects: 0
Study 19707065 — intervention group
Group type: EXPERIMENTAL
Intervention: Paying for CE credit
Number of subjects: 0
Study 19707065 — intervention group
Group type: EXPERIMENTAL
Intervention: Modules read and hours spent
Number of subjects: 0
Study 19707065 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater resource use (time spent, modules read)
Number of subjects: 0
Study 19707065 — intervention group
Group type: COMPARATOR
Intervention: Control group (all modules at once)
Number of subjects: 0
Study 17430239 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising plasma insulin to levels that characterize patients with insulin resistance
Number of subjects: 0
Study 15029217 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study 15029217 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study 12094124 — intervention group
Group type: EXPERIMENTAL
Intervention: GL+CR trial (glucose plus creatine)
Number of subjects: 5
Study 12094124 — intervention group
Group type: COMPARATOR
Intervention: GL trial (glucose)
Number of subjects: 5
Study 9854223 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hCG level > 1/150 and morphological ultrasonography between 18 and 20 weeks gestation
Number of subjects: 5163
Study 9854223 — intervention group
Group type: COMPARATOR
Intervention: Screening with serum markers alone
Number of subjects: 5163
Study 7620686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 0
Study 7620686 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study 7620686 — intervention group
Group type: COMPARATOR
Intervention: Prednicarbate
Number of subjects: 0
Study 7620686 — intervention group
Group type: COMPARATOR
Intervention: Base preparation (vehicle)
Number of subjects: 0
Study 2134659 — intervention group
Group type: EXPERIMENTAL
Intervention: He‐Ne‐Laser treatment
Number of subjects: 90
Study 30763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (3.1 mg daily, b.i.d.)
Number of subjects: 68
Study 30763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 31586376 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based depression improvement program
Number of subjects: 128
Study 31586376 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 26843101 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with DKA
Number of subjects: 57
Study 26100101 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking
Number of subjects: 106
Study 24975522 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic peanuts (HOP)
Number of subjects: 65
Study 24975522 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 65
Study 24975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional peanuts (CVP)
Number of subjects: 65
Study 24975522 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (CT, CVP, HOP)
Number of subjects: 65
Study 24975522 — intervention group
Group type: COMPARATOR
Intervention: Control (CT) and Conventional peanuts (CVP)
Number of subjects: 65